Additional Paid In Capital - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.1 PLN -1.64% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ryvu Therapeutics SA
Additional Paid In Capital Peer Comparison

Comparables:
I
IGN
M
MDB
S
SLV

Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Additional Paid In Capital
zł519.7m
CAGR 3-Years
23%
CAGR 5-Years
27%
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Medicofarma Biotech SA
WSE:MDB
Additional Paid In Capital
zł8.9m
CAGR 3-Years
177%
CAGR 5-Years
84%
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Additional Paid In Capital
zł109.4m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ryvu Therapeutics SA's Additional Paid In Capital?
Additional Paid In Capital
519.7m PLN

Based on the financial report for Mar 31, 2024, Ryvu Therapeutics SA's Additional Paid In Capital amounts to 519.7m PLN.

What is Ryvu Therapeutics SA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
27%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Ryvu Therapeutics SA have been 23% over the past three years , 27% over the past five years .

Back to Top